Stock Track | Intellia Therapeutics Soars 5.96% in Pre-Market on Strong Q4 Earnings Beat and Positive Pipeline Updates

Stock Track

Feb 26

Intellia Therapeutics' stock surged 5.96% in pre-market trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.

The biotech company reported quarterly earnings that significantly exceeded analyst expectations. Intellia posted a loss of $0.83 per share, beating the consensus estimate of a $0.96 loss by 13.72%. More impressively, the company reported quarterly sales of $23.017 million, which surpassed the $12.812 million estimate by 79.65% and represented a 78.79% increase over the same period last year.

Beyond the financial beat, Intellia provided encouraging business updates. The company ended 2025 with $605.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2027. On the pipeline front, the company anticipates topline Phase 3 data for its lonvo-z treatment for hereditary angioedema by mid-2026, with a planned BLA submission in the second half of 2026 and an anticipated U.S. launch in the first half of 2027. Additionally, the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for nex-z in ATTR amyloidosis in late January, allowing the company to resume enrollment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1194955859"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194955859\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194955859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194955859","market":"nz","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Soars 5.96% in Pre-Market on Strong Q4 Earnings Beat and Positive Pipeline Updates","media":"Stock Track","content":"<p>Intellia Therapeutics' stock surged 5.96% in pre-market trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.</p><p>The biotech company reported quarterly earnings that significantly exceeded analyst expectations. Intellia posted a loss of $0.83 per share, beating the consensus estimate of a $0.96 loss by 13.72%. More impressively, the company reported quarterly sales of $23.017 million, which surpassed the $12.812 million estimate by 79.65% and represented a 78.79% increase over the same period last year.</p><p>Beyond the financial beat, Intellia provided encouraging business updates. The company ended 2025 with $605.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2027. On the pipeline front, the company anticipates topline Phase 3 data for its lonvo-z treatment for hereditary angioedema by mid-2026, with a planned BLA submission in the second half of 2026 and an anticipated U.S. launch in the first half of 2027. Additionally, the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for nex-z in ATTR amyloidosis in late January, allowing the company to resume enrollment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Soars 5.96% in Pre-Market on Strong Q4 Earnings Beat and Positive Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Soars 5.96% in Pre-Market on Strong Q4 Earnings Beat and Positive Pipeline Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics' stock surged 5.96% in pre-market trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.</p><p>The biotech company reported quarterly earnings that significantly exceeded analyst expectations. Intellia posted a loss of $0.83 per share, beating the consensus estimate of a $0.96 loss by 13.72%. More impressively, the company reported quarterly sales of $23.017 million, which surpassed the $12.812 million estimate by 79.65% and represented a 78.79% increase over the same period last year.</p><p>Beyond the financial beat, Intellia provided encouraging business updates. The company ended 2025 with $605.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2027. On the pipeline front, the company anticipates topline Phase 3 data for its lonvo-z treatment for hereditary angioedema by mid-2026, with a planned BLA submission in the second half of 2026 and an anticipated U.S. launch in the first half of 2027. Additionally, the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for nex-z in ATTR amyloidosis in late January, allowing the company to resume enrollment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1194955859","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194955859","pubTimestamp":1772109282,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics' stock surged 5.96% in pre-market trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.The biotech company reported quarterly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"股票追踪|Intellia Therapeutics盘前飙升5.96%，得益于强劲的第四季度盈利和积极的管道更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics' stock surged 5.96% in pre-market trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.The biotech company reported quarterly earnings that significantly exceeded analyst expectations. Intellia posted a loss of $0.83 per share, beating the consensus estimate of a $0.96 loss by 13.72%. More impressively, the company reported quarterly sales of $23.017 million, which surpassed the $12.812 million estimate by 79.65% and represented a 78.79% increase over the same period last year.Beyond the financial beat, Intellia provided encouraging business updates. The company ended 2025 with $605.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2027. On the pipeline front, the company anticipates topline Phase 3 data for its lonvo-z treatment for hereditary angioedema by mid-2026, with a planned BLA submission in the second half of 2026 and an anticipated U.S. launch in the first half of 2027. Additionally, the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for nex-z in ATTR amyloidosis in late January, allowing the company to resume enrollment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}